---
title: "Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030"
description: "Eli Lilly's stock price has been steadily increasing since the start of 2020, growing by 562.57% and currently trading at $875.99. The company's market capitalization has also seen significant growth,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/209736465.md"
published_at: "2024-07-24T16:46:54.000Z"
---

# Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

> Eli Lilly's stock price has been steadily increasing since the start of 2020, growing by 562.57% and currently trading at $875.99. The company's market capitalization has also seen significant growth, from $100 billion to $740 billion. The future of Eli Lilly's stock will depend on factors such as projected revenue, net income, and the success of its drug pipeline. Analysts have set a one-year price target of $898, with varying opinions on the stock's performance. The company's focus on innovation, strategic acquisitions, and operational efficiency are expected to drive future growth.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 562.57% and currently trading at $875.99.

The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.

But as investors, we care about the stock price years down the line, what Eli Lilly will do in the next 3 to 5 years and beyond.

That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.

Other “experts” look at past growth rates and assign future stock prices off those past numbers. However we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly stock in the future.

## **Eli Lilly’s Recent Stock Success**

How did Eli Lilly’ stock price soar so much in the past few years? Lets take a look at the numbers:

Share Price

Revenues\*

Net Income\*

2016

$80.36

$21.22

$2.74

2017

$77.55

$19.94

($0.21)

2018

$122.13

$21.49

$3.23

2019

$140.83

$22.32

$8.32

2020

$206.46

$24.54

$6.19

2021

$238.31

$28.32

$5.58

2022

329.07

$28.54

$6.25

2023

$745.91

$34.12

$5.24

\*Revenue and Net Income in Billions

Since 2016, Eli Lilly’s revenue grew 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see a 828% increase in share price, however investor sentiment for the next line of drugs front ran the stock price.

For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.

This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?

## **3 Key Drivers of Eli Lilly Stock**

1.  **Innovated Drug Pipeline**: The current drug pipeline is loaded with several very high potential drugs in development. Mounjaro, Zepbound and Jardiance in the cardiometabolic category, Taltz in immunology and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential.
2.  **Strategic Acquisitions**: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.
3.  **Operational Efficiency:** With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.

## **Eli Lilly (LLY) Stock Price Prediction in 2025**

The current Wall Street consensus 1 year price target of Eli Lilly stock is $898, which is 2.51% higher than today’s price of $875.99.

Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1 year price targets as high as $1,100 and as low as $540.00.

**24/7 Wall Street’s** sets its 1 year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as following:

Endocrinology

$735/ share

Oncology

$122/ Share

Cardiovascular

$4/ Share

Neuroscience

$16/ Share

Immunology

$38/ Share

Others and Pipeline

$110/ Share

Cash

$17/ Share

## **Eli Lilly’s Share Price Estimates 2025-2030**

Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate at the market value of the company by assigning a price to earnings multiple.

**Revenue**

**Net Income**

**EPS**

**2025**

$52.8

$17.29

19.11

**2026**

$62.5

$22.49

25.03

**2027**

$70.87

$27.12

30.39

**2028**

$80.68

$32.2

25.97

**2029**

$87.99

$36.45

40.58

**2030**

$96.67

$41.12

46.29

\*Revenue and net income reported in billions

## Eli Lilly Price Forecast and Prediction for 2025:

**Price Target:** $1140.00  
**Upside:** 30.14%  
We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.

## Eli Lilly Price Forecast and Prediction for 2026:

**Price Target:** $1250.00  
**Upside:** 42.70%  
For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1251.50. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.

## Eli Lilly Price Forecast and Prediction for 2027:

**Price Target:** $1520.00  
**Upside:** 73.52%

In 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1519.50. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.

## Eli Lilly Price Forecast and Prediction for 2028:

**Price Target:** $1300.00  
**Upside:** 48.40%  
With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1298.50. The slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.

## Eli Lilly Price Forecast and Prediction for 2029:

**Price Target:** $1623.00  
**Upside:** 85.28%  
By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.20. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.

## Eli Lilly Price Forecast and Prediction for 2030:

**Price Target:** $1850.00  
**Upside:** 111.19%  
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1851.60. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.

Year

Price Target

% Change From Current Price

2025

$1146.60

Upside of 31.45%

2026

$1251.50

Upside of 44.70%

2027

$1519.50

Upside of 73.52%

2028

$1298.50

Upside of 48.40%

2029

$1623.20

Upside of 85.28%

2030

$1851.60

Upside of 111.19%

## Recent Amazon Stock Updates and News

**7/23/2024**

Eli Lilly will announced 2nd quarter earnings August 8th and analyst are anticipating $2.766 earnings per share which is 31% over last years earnings for the same quarter. Revenue is expected to come in at $10 billion, which is a 20% year-over-year gain.

**7/22/2024**

Eli Lilly announced Chinese approval for its weight loss drug, tirzepatide. This intensifies competition with Novo Nordisk, whose weight loss drug Wegovy was approved in China in June. Both companies are vying for the growing weight-loss market, projected to exceed $100 billion globally by the decade’s end.

## **Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)**

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| DELL, SPOT, UNH：全球最大的對沖基金正在市場中尋找抄底機會 | 橋水基金（Bridgewater Associates），全球最大的對沖基金，管理資產達 1360 億美元，在 2025 年第四季度對錶現不佳的股票進行了重大投資，包括戴爾（DELL）、Spotify（SPOT）和聯合健康（UnitedHe | [Link](https://longbridge.com/en/news/276384705.md) |
| 諾和諾德的 Wegovy 藥片在上市首月取得了強勁的使用量，表明肥胖症口服 GLP-1 藥物的需求正在擴大 | 諾和諾德公司的 Wegovy®（塞馬魯肽）藥丸於 2025 年 12 月獲得 FDA 批准，醫生的使用率非常高，首月內超過 70% 的醫生開處方。該口服 GLP-1 療法預計將擴大肥胖治療市場，非開處方醫生中有很高的開處方意向。禮來公司的  | [Link](https://longbridge.com/en/news/276452735.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
